Prostate cancer trials in China

In China 252 Also abroad 1481

252 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Beijing, Guangzhou, Shanghai
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
No phaseNot yet taking people in China
Non-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY
Where
Beijing, Hefei, Shanghai
People
400
Run by
Shanghai East Hospital
See details and how to joinNCT07887321
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiaxing, Kunming, Nanchong, Nanjing, Nantong, Ningbo, Shanghai, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuxi, Xi'an, Yantai
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 1/2Taking people
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Where
Jinan, Shanghai
Age
18 years and over
People
307
Run by
Evopoint Biosciences Inc.
See details and how to joinNCT06702995
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Suzhou, Wuhan, Xi'an
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 1Taking people
A Phase I Trial of A-CAR032 in Participants With mCRPC
Where
Beijing, Hangzhou, Wuhan, Xuzhou
Age
18 years and over
People
27
Run by
Shanghai AbelZeta Ltd.
See details and how to joinNCT07344311
Phase 3Taking people
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan, Wuhu, Yantai
Age
18 years and over
People
736 worldwide
Run by
BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Changsha, Chengdu, Guangzhou, Nanjing, Wenzhou
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 3Taking people
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
Age
18 years to 100 years
People
940 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06855277
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jiaxing, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nantong, Ningbo, Qingdao, Shandong, Shanghai, Wenzhou, Wuhan, Xi'an
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Not yet taking people in China
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
Where
Beijing, Chengdu, Shanghai
Age
18 years and over
People
1,044
Run by
Hinova Pharmaceuticals Inc.
See details and how to joinNCT07875881
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua, Lanzhou, Nanchang, Ningbo, Shanghai, Shenyang, Sichuan, Suining, Tianjin, Wuhan, Wuhu, Xiamen, Yangzhou, Zhuhai
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Beijing, Changsha, Chongqing, Guangzhou, Hangzhou, Huai'an, Jinan, Lanzhou, Nanjing, Nantong, Ningbo, Shanghai, Suining, Suzhou, Wenzhou, Wuhan, Wuhu, Xi’an
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1Taking people
DEC003M in Prostate Cancer
Where
Beijing, Chengdu, Chongqing, Hangzhou, Suzhou, Wenzhou
Age
18 years and over
People
110
Run by
Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07657806
Phase 2Taking people
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jiaxing, Jinan, Nanjing, Nantong, Ningbo, Wenzhou, Wuhan
Age
18 years and over
People
182
Run by
TransThera Sciences (Nanjing), Inc.
See details and how to joinNCT07871110
Phase 1/2Taking people
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Shanghai, Suzhou, Tianjin, Wuhan, Wuxi, Zhengzhou
Age
18 years and over
People
90
Run by
Bivision Pharmaceuticals, Inc.
See details and how to joinNCT06139575
Phase 1/2Taking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
Beijing
Age
18 years and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
No phaseTaking people
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
Where
Shanghai
Age
55 years and over
People
90
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07856017
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
Guangzhou
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
No phaseNot yet taking people in China
CascadeDiagnose Prostate MRI
Where
Guigang, Guilin, Liuzhou, Nanning, Wuzhou
Age
18 years and over
People
3,000
Run by
First Affiliated Hospital of Guangxi Medical University
See details and how to joinNCT07844304
Phase 1Taking people
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Where
Beijing, Fuzhou, Hangzhou, Shanghai, Zhengzhou
Age
18 years and over
People
88 worldwide
Run by
Acerand Therapeutics (Hong Kong) Limited
See details and how to joinNCT06801236
Phase 1Taking people
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
Where
Shanghai
Age
18 years to 80 years
People
320 worldwide
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07711184
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1Taking people
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Where
Beijing, Changsha, Hangzhou
Age
18 years to 75 years
People
110
Run by
Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT06926283
Phase 1Taking people
A Study of DXC014 in Patients With Advanced Solid Tumors.
Where
Beijing, Changsha, Hangzhou, Nanchang, Qingdao
Age
18 years and over
People
150
Run by
Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07177937